Vitiligo and melanoma-associated hypopigmentation (MAH):shared and discriminative features;Vitiligo und melanom-assoziierte hypopigmentierung (MAH):gemeinsamkeiten und unterschiede

JDDG - Journal of the German Society of Dermatology

Volumn 6, Issue 12, 2008, Pages 1053-1059

  Hartmann, Anke ^a   Bedenk, Christina ^a   Keikavoussi, Petra ^a   Becker, Jürgen C ^a   Hamm, Henning ^a   Bröcker, Eva Bettina ^a,b  

^a Universität Würzburgy

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Autoimmunity; Hypopigmentation; Melanoma; Vitiligo

Indexed keywords

HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; INTERFERON;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; FAMILY HISTORY; FEMALE; GENOTYPE; HAPLOTYPE; HISTOLOGY; HISTORY; HUMAN; HUMAN TISSUE; HYPOPIGMENTATION; IMMUNOHISTOLOGY; LEUKODERMA; MALE; MELANOMA; NEVUS; PHOTOGRAPHY; SCORING SYSTEM; SEROLOGY; TRUNK; VITILIGO;

EID: 57449105935     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2008.06755.x     Document Type: Article

References (28)

1. Nordlund JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne JP. The pigmentary system: physiology and pathophysiology, 2nd edition, Blackwell Publ., USA, 2006.
2. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 1998 139 : 798 805.
3. Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998 188 : 1203 1208.
4. Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, Ardigó M, Borroni G, Martinetti M, Badulli C, Necker A, Giachino C. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001 117 : 326 332.
5. Hartmann A, Bröcker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004 64 : 89 107.
6. Hartmann A, Lurz C, Hamm H, Bröcker EB, Hofmann UB. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol 2005 44 : 736 742.
7. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003 139 : 581 585.
8. Hartmann A, Bröcker EB, Hamm H. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-months prospective study. Acta Derm Venereol 2008, in press.
9. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983 9 : 689 696.
10. Schallreuter KU, Levening C, Berger J. Vitiligo and Cutaneous Melanoma. A Case Study. Dermatologica 1991 183 : 239 245.
11. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Tumor Immunol 1996 19 : 81 84.
12. Koh HK, Sober AJ, Nakagawa H, Albert DM, Mihm MC, Fitzpatrick TB. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol 1983 9 : 696 708.
13. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypo-pigmentation in malignant melanoma. Arch Dermatol 1987 123 : 1053 1055.
14. Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol 2001 117 : 1464 1470.
15. Pedersen LØ, Vetter CS, Mingari MC, Andersen MH, thor Straten P, Bröcker EB, Becker JC. Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report. J Invest Dermatol 2002 118 : 595 599.
16. Becker JC, Guldberg P, Zeuthen J, Bröcker E.B.,Straten PTh. Accumulation of identical T Cells in Melanoma and Vitiligo-like Leukoderma. J Invest Dermatol. 1999 113 : 1033 1038.
17. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000 42 : 245 253.
18. Perfetti L, Cespa M, Nume A, Orecchia G. Prevalence of atopy in vitiligo. A preliminary report. Dermatologica 1991 182 : 218 220.
19. Chatain C, Ring J, Schallreuter KU. Total serum immunoglobulins and atopic symptoms in patients with vitiligo. Dermatology 1994 189 : 27 31.
20. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH, Fleischer B. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994 102 : 145 149.
21. Müller CR. Populationsgenetische Parameter der Gewebemerkmale der deutschen Bevölkerung und ihre An-wendung bei der Suche nach nicht-ver-wandten Blutstammzellspendern. Dok-torarbeit. Universität Ulm, 2000.
22. Schallreuter KU, Levenig C, Kühnl P, Löliger C, Hohl-Tehari M, Berger J. Hi-stocompatibility antigens in vitiligo: Hamburg study on 102 patients from northern Germany. Dermatology 1993 187 : 186 192.
23. Ando I, Chi HI, Nakagawa H, Otsuka F. Difference in clinical features and HLA antigens between familial and non-familial vitiligo of non-segmental type. Br J Dermatol 1993 129 : 408 410.
24. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006 354 : 709 718.
25. Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 2007 121 : 2562 2566.
26. Ladewig G, Reinhold U, Thirkill CE, Kerber A, Tilgen W, Pföhler C. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. Br J Dermatol 2005 152 : 931 938.
27. Borkowski LM, Grover S, Fishman GA, Jampol LM. Retinal findings in melanoma-associated retinopathy. Am J Ophthalmol 2001 132 : 273 275.
28. Rodriguez-Cuevas S, López-Chavira A, Zepeda del Rio G, Cuadra-Garcia I, Fernàndez-Diez J. Prognostic significance of cutaneous depigmentation in Mexican patients with malignant melanoma. Arch Med Res 1998 29 : 155 158.